Regenerative Therapies

Mesenchymal stromal cells have been shown to exhibit a great therapeutical potential in various diseases. However, up until now clinical application was limited by the lack of availability of clinical grade MSC in large quantities. A method has been developed by our group to isolate fetal MSC at clinical grade. The method was patented (DE102016114043B3) and is currently in migration into a university-based spin-off company. Within the MASC-collaboration these MSC are currently tested in clinical trials (OHRI, CHEO, SCRM).

Currently, this cells are also used as a therapeutic agent to treat Covid-19 associated ARDS. Furthermore, a trial is planned to test efficacy in patients with steroid refractory GvHD.

The project is funded by the Bundesministerium für Wirtschaft with 1.4 Mill €.

Group

Daniel Freund, Marius Möbius, Nadine Münch, Mario Rüdiger, Tino Hammer

Collaborations

Sinclair Center for Regenerative Medicine (SCRM), Ottawa Hospital Research Institute (OHRI) and the Cildren`s Hospital of Eastern Ontario (CHEO); Ottawa, Canada;

University of Texas Health Sciences Center at San Antonio (UTHSCSA), USA;

King`s College, London (KCL), UK;

Medizinische Hochschule Hannover (MHH);

Center for Pediatric Clinical Studies, Universität Tübingen (CPCS);

Publications

Late Rescue Therapy with Cord-Derived Mesenchymal Stromal Cells for Established Lung Injury in Experimental Bronchopulmonary Dysplasia. O'Reilly M, Möbius MA, Vadivel A, Ionescu L, Fung M, Eaton F, Greer JJ, Thébaud B. Stem Cells Dev. 2020 Mar 15;29(6):364-371. doi: 10.1089/scd.2019.0116

How to introduce MSC-based therapy for the developing lung safely into clinical care? Rüdiger M, Kirpalani H, Steinhorn R, Davis JM, Thebaud B. Pediatr Res. 2020 Sep;88(3):365-368. doi: 10.1038/s41390-020-0758-0

Oxygen Disrupts Human Fetal Lung Mesenchymal Cells. Implications for Bronchopulmonary Dysplasia. Möbius MA, Freund D, Vadivel A, Koss S, McConaghy S, Ohls RK, Rüdiger M, Thébaud B. Am J Respir Cell Mol Biol. 2019 May;60(5):592-600. doi: 10.1165/rcmb.2018-0358OC

Impaired Angiogenic Supportive Capacity and Altered Gene Expression Profile of Resident CD146+ Mesenchymal Stromal Cells Isolated from Hyperoxia-Injured Neonatal Rat Lungs. Collins JJP, Lithopoulos MA, Dos Santos CC, Issa N, Möbius MA, Ito C, Zhong S, Vadivel A, Thébaud B. Stem Cells Dev. 2018 Aug 15;27(16):1109-1124. doi: 10.1089/scd.2017.0145

Bronchopulmonary Dysplasia: Where Have All the Stem Cells Gone?: Origin and (Potential) Function of Resident Lung Stem Cells. Möbius MA, Thébaud B. Chest. 2017 Nov;152(5):1043-1052. doi: 10.1016/j.chest.2017.04.173

Human Umbilical Cord Mesenchymal Stromal Cells Improve Survival and Bacterial Clearance in Neonatal Sepsis in Rats. Zhu Y, Xu L, Collins JJP, Vadivel A, Cyr-Depauw C, Zhong S, Mense L, Möbius MA, Thébaud B. Stem Cells Dev. 2017 Jul 15;26(14):1054-1064. doi: 10.1089/scd.2016.0329

Cell Therapy for Bronchopulmonary Dysplasia: Promises and Perils. Möbius MA, Thébaud B. Paediatr Respir Rev. 2016 Sep;20:33-41. doi: 10.1016/j.prrv.2016.06.001

Isolation of CD146+ Resident Lung Mesenchymal Stromal Cells form Rat Lungs. Collins JJ, Möbius MA, Thébaud B. J Vis Exp. 2016 Jun 17;(112):53782. doi: 10.3791/53782

Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. Möbius MA, Rüdiger M. Mol Cell Pediatr. 2016 Dec;3(1):18. doi: 10.1186/s40348-016-0046-6